NR 568 Final Exam Advanced Pharmacology
Adult-Gerontology Primary Care NP Actual Exam 2026/2027
- 100% Verified | Detailed Rationales - Pass Guaranteed - A+
Graded - 147 Questions with Answers
NR 568 Final Exam 2026-147 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NR 568 Final Exam (Advanced Pharmacology for
Adult-Gerontology Primary Care Nurse Practitioners) contains 200 verified questions with detailed
rationales. It covers all major pharmacological principles, drug classifications, and clinical applications
essential for the AGPCNP role. The content is aligned with the latest 2026/2027 guidelines and ensures
a thorough review for exam success.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic Nervous System Drugs
Cardiovascular Pharmacology
Respiratory Pharmacology
Endocrine Pharmacology
Gastrointestinal Pharmacology
Neurological and Psychiatric Pharmacology
Analgesics and Anti-inflammatory Agents
Antimicrobial Therapy
Hematologic Pharmacology
Dermatologic Pharmacology
Women's and Men's Health Pharmacology
Geriatric Pharmacology and Polypharmacy
Prescribing in Special Populations (Renal/Hepatic Impairment, Pregnancy, Lactation)
Drug Interactions and Adverse Effects
Patient Education and Adherence
Evidence-Based Prescribing and Guidelines
Legal and Ethical Aspects of Prescribing
Updates for 2026:
- Updated to reflect 2026/2027 clinical practice guidelines
- Revised to include new FDA-approved medications
- Enhanced rationales with evidence-based references
- Added case-based questions to simulate clinical decision-making
- Expanded coverage of geriatric-specific prescribing considerations
Abstract:
This exam preparation resource for NR 568 Final Exam provides a rigorous review of advanced pharmacology as
applied to adult-gerontology primary care. It encompasses 200 verified questions that span the entire curriculum,
from foundational pharmacokinetics to complex prescribing in older adults. Each question is accompanied by a
detailed rationale that explains the correct answer and why distractors are incorrect, reinforcing critical thinking.
The content is meticulously updated to align with 2026/2027 standards, ensuring relevance and accuracy. This
Page 1
,document is an indispensable tool for nurse practitioner students aiming to excel in their final pharmacology
examination and future clinical practice.
Keywords:
Advanced Pharmacology, Adult-Gerontology Primary Care, Nurse Practitioner, Exam Prep, NCLEX-style
Questions, Pharmacotherapeutics, Drug Interactions, Geriatric Prescribing
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale. Rationales explain the mechanism
of action, clinical application, and why the incorrect options are not appropriate. This format reinforces
understanding and aids in retention.
Compliance Checklist:
200 verified questions with answers
Detailed rationales for every question
Updated per 2026/2027 guidelines
Covers all major content areas of NR 568
Designed for A+ grading and exam success
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Pharmacology 1-20 Pharmacokinetics, Pharmacodynamics, Drug 10%
Receptors, Adverse Effects
Autonomic Nervous System 21-40 Cholinergic Agonists/Antagonists, 10%
Drugs Adrenergic Agonists/Antagonists
Cardiovascular Pharmacology 41-70 Antihypertensives, Antiarrhythmics, 15%
Antianginals, Heart Failure Drugs,
Anticoagulants
Respiratory Pharmacology 71-85 Bronchodilators, Corticosteroids, 7.5%
Antihistamines, Decongestants
Endocrine Pharmacology 86-110 Insulin, Oral Hypoglycemics, Thyroid 12.5%
Drugs, Corticosteroids, Sex Hormones
Gastrointestinal Pharmacology 111-125 Antacids, Proton Pump Inhibitors, 7.5%
Antiemetics, Laxatives, Antidiarrheals
Neurological and Psychiatric 126-145 Antiepileptics, Antidepressants, 10%
Pharmacology Antipsychotics, Anxiolytics, Parkinson's
Drugs
Analgesics and 146-160 Opioids, NSAIDs, Acetaminophen, 7.5%
Anti-inflammatory Agents Adjuvant Analgesics
Antimicrobial Therapy 161-180 Antibiotics, Antivirals, Antifungals, 10%
Antiparasitics
Special Populations and 181-200 Renal/Hepatic Dosing, Pregnancy/Lactation, 10%
Geriatrics Polypharmacy, Beers Criteria
Page 2
,Q1. A patient with chronic kidney disease (eGFR 28 mL/min) and type 2 diabetes is
on metformin 1000 mg twice daily. Which change in metformin therapy is most
appropriate, and what is the primary rationale?
A. Continue current dose; metformin is not renally cleared.
B. Reduce dose to 500 mg twice daily; risk of lactic acidosis increases with declining
eGFR.
C. Discontinue metformin immediately; it is absolutely contraindicated at this eGFR.
D. Switch to insulin glargine; metformin is ineffective at this eGFR.
Correct Answer: B. Reduce dose to 500 mg twice daily; risk of lactic acidosis
increases with declining eGFR.
Rationale: Metformin is renally excreted; at eGFR 30-45 mL/min, continuation is not
recommended, but if used, dose reduction is required. The risk of lactic acidosis rises as
eGFR falls below 45. Current guidelines suggest reducing the dose and monitoring renal
function closely. It is not absolutely contraindicated until eGFR <30, and it is not
ineffective.
Why Wrong:
A - Metformin is primarily renally cleared; continuing the same dose at eGFR 28 is
unsafe.
C - At eGFR 28, metformin is contraindicated, but the threshold is <30; however, the
question is about a dose reduction, not immediate discontinuation.
D - Metformin remains effective, but the issue is safety, not efficacy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 58.
Q2. Which pharmacodynamic principle best explains why a patient on a long-acting
beta-agonist (LABA) may require higher doses of a short-acting beta-agonist (SABA)
during an acute exacerbation?
A. Downregulation of beta-2 receptors due to chronic LABA exposure.
B. Competitive antagonism at the beta-2 receptor by the LABA.
C. Altered drug metabolism leading to reduced SABA bioavailability.
D. Increased vagal tone counteracting bronchodilation.
Correct Answer: A. Downregulation of beta-2 receptors due to chronic LABA
exposure.
Rationale: Chronic exposure to beta-2 agonists leads to receptor desensitization and
downregulation, reducing the efficacy of SABAs. This is a well-known pharmacodynamic
tolerance phenomenon. LABA does not antagonize the receptor; metabolism changes are
not the primary issue; vagal tone is not directly related.
Why Wrong:
B - LABA is an agonist, not an antagonist; it does not block SABA binding.
C - Pharmacodynamic tolerance is not due to metabolic changes.
Page 3
, D - Vagal tone may be altered, but the primary mechanism is receptor downregulation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 81.
Q3. A patient with heart failure with reduced ejection fraction (HFrEF) is started on
sacubitril/valsartan. Which laboratory value requires the most vigilant monitoring
during the first month of therapy?
A. Serum creatinine and potassium.
B. Liver function tests.
C. Complete blood count.
D. Serum magnesium.
Correct Answer: A. Serum creatinine and potassium.
Rationale: Sacubitril/valsartan combines an ARNI and an ARB, which can cause
hyperkalemia and worsening renal function, especially in patients with HFrEF. Monitoring
renal function and potassium is essential. Liver function, CBC, and magnesium are not the
primary monitoring parameters for this drug.
Why Wrong:
B - Liver toxicity is not a common adverse effect of sacubitril/valsartan.
C - No significant hematologic effects are expected.
D - Magnesium is not specifically monitored for this drug.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 34.
Q4. Which of the following best describes the interaction between clopidogrel and
omeprazole?
A. Omeprazole increases clopidogrel absorption, enhancing antiplatelet effect.
B. Omeprazole inhibits CYP2C19, reducing clopidogrel activation and antiplatelet
efficacy.
C. Clopidogrel increases omeprazole metabolism, reducing its acid suppression.
D. The combination increases the risk of gastrointestinal bleeding due to additive
effects.
Correct Answer: B. Omeprazole inhibits CYP2C19, reducing clopidogrel activation
and antiplatelet efficacy.
Rationale: Clopidogrel is a prodrug requiring CYP2C19 activation. Omeprazole is a
CYP2C19 inhibitor, which reduces the formation of the active metabolite, thereby
decreasing antiplatelet effect. This interaction is clinically significant. The other options
are incorrect.
Why Wrong:
A - Omeprazole does not increase absorption; it inhibits metabolic activation.
C - Clopidogrel does not significantly affect omeprazole metabolism.
D - The combination may reduce antiplatelet effect, not increase bleeding risk
Page 4
Adult-Gerontology Primary Care NP Actual Exam 2026/2027
- 100% Verified | Detailed Rationales - Pass Guaranteed - A+
Graded - 147 Questions with Answers
NR 568 Final Exam 2026-147 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NR 568 Final Exam (Advanced Pharmacology for
Adult-Gerontology Primary Care Nurse Practitioners) contains 200 verified questions with detailed
rationales. It covers all major pharmacological principles, drug classifications, and clinical applications
essential for the AGPCNP role. The content is aligned with the latest 2026/2027 guidelines and ensures
a thorough review for exam success.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic Nervous System Drugs
Cardiovascular Pharmacology
Respiratory Pharmacology
Endocrine Pharmacology
Gastrointestinal Pharmacology
Neurological and Psychiatric Pharmacology
Analgesics and Anti-inflammatory Agents
Antimicrobial Therapy
Hematologic Pharmacology
Dermatologic Pharmacology
Women's and Men's Health Pharmacology
Geriatric Pharmacology and Polypharmacy
Prescribing in Special Populations (Renal/Hepatic Impairment, Pregnancy, Lactation)
Drug Interactions and Adverse Effects
Patient Education and Adherence
Evidence-Based Prescribing and Guidelines
Legal and Ethical Aspects of Prescribing
Updates for 2026:
- Updated to reflect 2026/2027 clinical practice guidelines
- Revised to include new FDA-approved medications
- Enhanced rationales with evidence-based references
- Added case-based questions to simulate clinical decision-making
- Expanded coverage of geriatric-specific prescribing considerations
Abstract:
This exam preparation resource for NR 568 Final Exam provides a rigorous review of advanced pharmacology as
applied to adult-gerontology primary care. It encompasses 200 verified questions that span the entire curriculum,
from foundational pharmacokinetics to complex prescribing in older adults. Each question is accompanied by a
detailed rationale that explains the correct answer and why distractors are incorrect, reinforcing critical thinking.
The content is meticulously updated to align with 2026/2027 standards, ensuring relevance and accuracy. This
Page 1
,document is an indispensable tool for nurse practitioner students aiming to excel in their final pharmacology
examination and future clinical practice.
Keywords:
Advanced Pharmacology, Adult-Gerontology Primary Care, Nurse Practitioner, Exam Prep, NCLEX-style
Questions, Pharmacotherapeutics, Drug Interactions, Geriatric Prescribing
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale. Rationales explain the mechanism
of action, clinical application, and why the incorrect options are not appropriate. This format reinforces
understanding and aids in retention.
Compliance Checklist:
200 verified questions with answers
Detailed rationales for every question
Updated per 2026/2027 guidelines
Covers all major content areas of NR 568
Designed for A+ grading and exam success
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Pharmacology 1-20 Pharmacokinetics, Pharmacodynamics, Drug 10%
Receptors, Adverse Effects
Autonomic Nervous System 21-40 Cholinergic Agonists/Antagonists, 10%
Drugs Adrenergic Agonists/Antagonists
Cardiovascular Pharmacology 41-70 Antihypertensives, Antiarrhythmics, 15%
Antianginals, Heart Failure Drugs,
Anticoagulants
Respiratory Pharmacology 71-85 Bronchodilators, Corticosteroids, 7.5%
Antihistamines, Decongestants
Endocrine Pharmacology 86-110 Insulin, Oral Hypoglycemics, Thyroid 12.5%
Drugs, Corticosteroids, Sex Hormones
Gastrointestinal Pharmacology 111-125 Antacids, Proton Pump Inhibitors, 7.5%
Antiemetics, Laxatives, Antidiarrheals
Neurological and Psychiatric 126-145 Antiepileptics, Antidepressants, 10%
Pharmacology Antipsychotics, Anxiolytics, Parkinson's
Drugs
Analgesics and 146-160 Opioids, NSAIDs, Acetaminophen, 7.5%
Anti-inflammatory Agents Adjuvant Analgesics
Antimicrobial Therapy 161-180 Antibiotics, Antivirals, Antifungals, 10%
Antiparasitics
Special Populations and 181-200 Renal/Hepatic Dosing, Pregnancy/Lactation, 10%
Geriatrics Polypharmacy, Beers Criteria
Page 2
,Q1. A patient with chronic kidney disease (eGFR 28 mL/min) and type 2 diabetes is
on metformin 1000 mg twice daily. Which change in metformin therapy is most
appropriate, and what is the primary rationale?
A. Continue current dose; metformin is not renally cleared.
B. Reduce dose to 500 mg twice daily; risk of lactic acidosis increases with declining
eGFR.
C. Discontinue metformin immediately; it is absolutely contraindicated at this eGFR.
D. Switch to insulin glargine; metformin is ineffective at this eGFR.
Correct Answer: B. Reduce dose to 500 mg twice daily; risk of lactic acidosis
increases with declining eGFR.
Rationale: Metformin is renally excreted; at eGFR 30-45 mL/min, continuation is not
recommended, but if used, dose reduction is required. The risk of lactic acidosis rises as
eGFR falls below 45. Current guidelines suggest reducing the dose and monitoring renal
function closely. It is not absolutely contraindicated until eGFR <30, and it is not
ineffective.
Why Wrong:
A - Metformin is primarily renally cleared; continuing the same dose at eGFR 28 is
unsafe.
C - At eGFR 28, metformin is contraindicated, but the threshold is <30; however, the
question is about a dose reduction, not immediate discontinuation.
D - Metformin remains effective, but the issue is safety, not efficacy.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 58.
Q2. Which pharmacodynamic principle best explains why a patient on a long-acting
beta-agonist (LABA) may require higher doses of a short-acting beta-agonist (SABA)
during an acute exacerbation?
A. Downregulation of beta-2 receptors due to chronic LABA exposure.
B. Competitive antagonism at the beta-2 receptor by the LABA.
C. Altered drug metabolism leading to reduced SABA bioavailability.
D. Increased vagal tone counteracting bronchodilation.
Correct Answer: A. Downregulation of beta-2 receptors due to chronic LABA
exposure.
Rationale: Chronic exposure to beta-2 agonists leads to receptor desensitization and
downregulation, reducing the efficacy of SABAs. This is a well-known pharmacodynamic
tolerance phenomenon. LABA does not antagonize the receptor; metabolism changes are
not the primary issue; vagal tone is not directly related.
Why Wrong:
B - LABA is an agonist, not an antagonist; it does not block SABA binding.
C - Pharmacodynamic tolerance is not due to metabolic changes.
Page 3
, D - Vagal tone may be altered, but the primary mechanism is receptor downregulation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 81.
Q3. A patient with heart failure with reduced ejection fraction (HFrEF) is started on
sacubitril/valsartan. Which laboratory value requires the most vigilant monitoring
during the first month of therapy?
A. Serum creatinine and potassium.
B. Liver function tests.
C. Complete blood count.
D. Serum magnesium.
Correct Answer: A. Serum creatinine and potassium.
Rationale: Sacubitril/valsartan combines an ARNI and an ARB, which can cause
hyperkalemia and worsening renal function, especially in patients with HFrEF. Monitoring
renal function and potassium is essential. Liver function, CBC, and magnesium are not the
primary monitoring parameters for this drug.
Why Wrong:
B - Liver toxicity is not a common adverse effect of sacubitril/valsartan.
C - No significant hematologic effects are expected.
D - Magnesium is not specifically monitored for this drug.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 34.
Q4. Which of the following best describes the interaction between clopidogrel and
omeprazole?
A. Omeprazole increases clopidogrel absorption, enhancing antiplatelet effect.
B. Omeprazole inhibits CYP2C19, reducing clopidogrel activation and antiplatelet
efficacy.
C. Clopidogrel increases omeprazole metabolism, reducing its acid suppression.
D. The combination increases the risk of gastrointestinal bleeding due to additive
effects.
Correct Answer: B. Omeprazole inhibits CYP2C19, reducing clopidogrel activation
and antiplatelet efficacy.
Rationale: Clopidogrel is a prodrug requiring CYP2C19 activation. Omeprazole is a
CYP2C19 inhibitor, which reduces the formation of the active metabolite, thereby
decreasing antiplatelet effect. This interaction is clinically significant. The other options
are incorrect.
Why Wrong:
A - Omeprazole does not increase absorption; it inhibits metabolic activation.
C - Clopidogrel does not significantly affect omeprazole metabolism.
D - The combination may reduce antiplatelet effect, not increase bleeding risk
Page 4
